Compare Credo Technology Group Holding Ltd (CRDO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Eli Lilly And Co — how do they compare? Credo Technology Group Holding Ltd trades at $216.38 (market cap $39.82B), while Eli Lilly And Co trades at $1,177 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 26.1× Credo Technology Group Holding Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Eli Lilly And Co for 93 Days on average.
| CRDO | LLY | |
|---|---|---|
Market Cap | $39.82B | $1.04T |
Volume | 9,451,558 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $302.52 | $1.28K |
52-Week Low | $87.81 | $799.57 |
Typical Hold Time | 22 Days | 93 Days |
Enterprise Value | $39.08B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $213.95, down 2.75% today but maintains strong technical support near $214. The company demonstrates exceptional fundamental performance with 114.7% YoY revenue growth and 33.83% net margins. Recent earnings beats and bullish analyst consensus at 87.5% buy ratings support the positive outlook. Technical indicators show bullish moving averages while oscillators remain neutral, with key support at $204 and resistance at $222.
CRDO presents compelling growth potential driven by AI infrastructure demand, with consensus price target of $267.33 offering 25% upside. Risks include premium valuation (P/E 74.6) and customer concentration, but strong cash flow generation and expanding optical business provide fundamental support. The stock's recent pullback may offer entry opportunity for growth investors.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
